Published: Jan. 5, 2026 at 9:01 a.m. ET
A small biopharma company said its experimental depression drug is moving into Phase 3 trials, sending its shares soaring about 35% in premarket trading on Monday.
GH Research GHRS now plans to put GH001 into late-stage research sometime this year after the FDA lifted a clinical hold on the psychedelic, which it’s testing in patients with treatment-resistant depression. Cantor Fitzgerald analysts expect the trial to kick off in the second half of the year.
